Somatropin/mecasermin combination therapeutics - Genentech/Tercica

Drug Profile

Somatropin/mecasermin combination therapeutics - Genentech/Tercica

Alternative Names: Growth hormone/insulin-like growth factor-1; Increlex/NutropinAq; rhGH/rhIGF-1

Latest Information Update: 21 Jul 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Genentech; Tercica
  • Developer Ipsen Biopharmaceuticals; Tercica
  • Class Biological peptides; Growth factors; Growth hormones; Peptides
  • Mechanism of Action Insulin-like growth factor I stimulants; Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Short stature; Somatotropin deficiency

Most Recent Events

  • 17 Sep 2009 Preliminary safety and efficacy data from a phase II study in children with short stature associated with low level of IGF-1 released by Ipsen
  • 16 Oct 2008 Tercica has been acquired by Ipsen
  • 25 Jan 2008 Phase-II clinical trials in Short stature in children in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top